Aim To compare efficacy and toxicity of bolus application of chemotherapy protocol, oxaliplatin, fluorouracil (bolus), leucovorin (folfox) between two groups of patients in the therapy of metastatic colorectal carcinoma (mCRC). Methods A total of 63 patients were treated for mCRC in the period January 2009 – January 2010 at the Department of Oncology of the Cantonal Hospital Zenica, Bosnia and Herzegovina (first group, 30 patients) and at the Department of Oncology of the Clinical Hospital Centre Bežanijska kosa in Belgrade, Serbia, in the period January 2005 – January 2006 (second group, 33 patients). The patients were treated according the same protocol, i.v. bolus infusion, but in different day intervals (D), 1, 8, 15/28 days or D1-D5/28 days, respectively. In all patients the following factors were analyzed: tumor response, overall survival (OS), progression free survival, hematological and non-hematological toxicity . Results Colon was the primary localization in almost two thirds of patients. There was no statistically significant difference between the groups according to the age, hematological and non-hematological toxicity, as well as in achieved OS. Progression free survival expressed in months was in average 5 months though with a large range between minimal and maximal survival time. Conclusion Both groups have shown equivalent efficacy to applied chemotherapy protocols. Overall survival in the two groups matched data from the literature. Further research should confirm success of the combination of chemotherapy protocols and their combination with the biological therapy.
Tournigand C, Andre T, Achille E, Liedo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse seguencein advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;229–37.
2.
Rex D, Anderson J, Schoenfeld J, Burke P, Inadomi C, J. American College of Gastroenterology Guidelines for colorectal cancer screening. Am J Gastroenterology. 2008;739–50.
3.
Vita D, Lawrence V, Rosenberg T, S. Cancer Principels & Practice of Oncology. 2008;
4.
Benson A, Venok A, Bekall-Saab T, Chan, Ch YJ, Cooper H, et al. Rectal Cancer. 20 th Annual Ed. 2015;
5.
V. 2015;
6.
Benson A, Venok A, Bekall-Saab T, Chan, Ch YJ, Cooper H, et al. Freedman-Cass D. National Comprehensive Cancer Network. (NCCN) Clinical Practice Gudelines in Oncology.
7.
Kopetz S, Chang G, Overman M, Enq C, Sargent D, Lasron D, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;3677–83.
8.
Krivokapić Z. Karcinom rektuma. Beograd: Zavod za udžbenike. 2012;
9.
Cutsem E, Henning C, Hitre K, Zaluski E, J, Cc CR, et al. Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. N Engl J Med. 2009;1408–17.
10.
Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin -based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;2013–9.
11.
Popov I, Tarabar D, Jovanović D, Kovčin V, Radić S, Micev M, et al. Efficacy and safety of bevacizumab in combination with oxaliplatin, irinotecan and fluoropyrimidine-based therapy in advanced colorectal cancer. Arch Oncol. 2007;10–4.
12.
Kovčin V, Ješić R, Krivokapić Z, Andrić Z, Pavlović A. Xeloda as first-line chemotherapy of metastatic colorectal cancer-our expirence. Arch Oncology. 2002;249–52.
13.
Souglakos J, Androulakis N, Syrigos, Polyzos N, Ziras, Athanasiadis S, et al. FOLFOXIRI (folin acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folin acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomized III trail from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;798–805.
14.
Maindrault-Goebel F, Leido G, Chibaudel B, Mineur T, Andre M, Bennamoun M, et al. OPTIMOX2, a large randomized phase II study of maintenance therapy of chemotherapy-free intervals(CFI) after FOLFOX in patints with metastatic colorecral cancer (MRC). J Clin Oncol. 2006;147.
15.
Goldberg R, Morton R, Sargent D, Fuchs C, Ramanathan R, Williamson S, et al. Oxaliplatin (oxal) or CPT-11 + 5Fluorouracil/Leucovorin or Oxal +CPT-11in advanced colorectal cancer: Initial toxicity and response data from a GI Intergroup study. Pro Am Soc Clin Oncol. 2002;511.
16.
Benson A. Epidemiology, disease progression and economic burden of colorectum cancer. JMCP. 2007;5–18.
Fazio V, Church J, Delaney C. Current Therapy Colon and Rectal Surgery. 2 nd ed. 2005;379–88.
19.
Cochen A. Surgical consideration in patients with cancer of the colon and rectum. Semin Oncol. 1991;381–419.
20.
U. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Inter Med. 2008;627–37.
21.
Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on now evidence. Gastroenterology. 2003;544–60.
22.
Koretz R. Malignat polyp: are they sheep in wolves , clothing? Ann Intern Med. 1993;63–8.
23.
Winawer S. Natural history of colorectal cancer. Am J Med. 1999;3S-6S.
24.
Fuchs C, Giovannucci E, Colditz G, Hunter D, Speizer F, Willett W. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;1669–74.
25.
Ashan H, Neugut A, Garbovski G, Jacobson J, Forde K, Treat M, et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann intern Med. 1998;900–5.
26.
Eduard V, Mirko Š, Zvonko K, Marija P, Damir P, Damir G, et al. Medicinska naklada. 2013;
27.
Incidencija i mortalitet od raka u centralnoj Srbiji 2009. Beograd: Insititut za javno zdravlje. Jovan Jovanović Batut. 2011;
28.
Fearlay J, Steliarova-Foucher E, Loret-Tieulent J, Rosso S, Coebergh J, Comber H, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. EJC. 2013;1374–403.
29.
Vrdoljak E, Wojtukeiwicz M, Pienkowski T, Bodoky G, Berzinec P, Finek J, et al. Cancer epidemiology in Central and South Eastern European countries. CMJ. 2011;478–87.
30.
Boyle P, Levin B. World cancer report. Lyon: International Agency for Research on Cancer. 2008;
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
